Risk of progression of Barrett's esophagus in patients with cirrhosis

被引:3
|
作者
Apfel, Tehilla [1 ]
Lopez, Rocio [1 ]
Sanaka, Madhusudhan R. [1 ]
Thota, Prashanthi N. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA
关键词
Liver cirrhosis; Barrett's esophagus; Dysplasia; Esophageal neoplasm; Progression; NONALCOHOLIC FATTY LIVER; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; METABOLIC SYNDROME; ADENOCARCINOMA; VARICES; METAANALYSIS; ADIPOKINES; DISEASE;
D O I
10.3748/wjg.v23.i18.3287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To study Barrett's esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1: 4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/ EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person-years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person-years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR = 7.9, 95% CI: 2.0-30.9, P = 0.003). CONCLUSION Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
引用
收藏
页码:3287 / 3294
页数:8
相关论文
共 50 条
  • [1] Risk of progression of Barrett's esophagus in patients with cirrhosis
    Tehilla Apfel
    Rocio Lopez
    Madhusudhan R Sanaka
    Prashanthi N Thota
    World Journal of Gastroenterology, 2017, (18) : 3287 - 3294
  • [2] Histological features indicate the risk of progression of patients with Barrett's esophagus
    Chen, Tiane
    Ly, Hong
    Stairs, Douglas B.
    Jackson, Christopher R.
    Chen, Guoli
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 266
  • [3] Risk factors for neoplastic progression in Barrett's esophagus
    Elizabeth F Wiseman
    Yeng S Ang
    World Journal of Gastroenterology, 2011, 17 (32) : 3672 - 3683
  • [4] Barrett's esophagus - Reducing the risk of progression to adenocarcinoma
    Reynolds, JC
    Waronker, M
    Pacquing, MS
    Yassin, RR
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) : 917 - +
  • [5] Risk factors for neoplastic progression in Barrett's esophagus
    Wiseman, Elizabeth F.
    Ang, Yeng S.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (32) : 3672 - 3683
  • [6] Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus
    Peleg, Noam
    Schmilovitz-Weiss, Hemda
    Shamah, Steven
    Schwartz, Ariel
    Dotan, Iris
    Sapoznikov, Boris
    ENDOSCOPY, 2021, 53 (08) : 774 - 781
  • [7] Higher risk of neoplastic progression of Barrett's esophagus in patients with systemic sclerosis
    Anilkumar, Mythri
    Alkhayyat, Motasem
    Grewal, Udhayvir S.
    Sanaka, Madhusudhan R.
    Thota, Prashanthi N.
    GASTROENTEROLOGY REPORT, 2021, 9 (06): : 595 - 596
  • [8] Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk (BEAR) Score
    Brown, Craig S.
    Lapin, Brittany
    Goldstein, Jay L.
    Linn, John G.
    Carbray, Joann M.
    Talamonti, Mark S.
    Ujiki, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : S16 - S17
  • [9] To study the incidence of Barrett's esophagus in patients with liver cirrhosis
    Anwar, N
    Komatineni, N
    Mehta, S
    Nompleggi, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S37 - S37
  • [10] Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women
    Allen, James E.
    Desai, Madhav
    Roumans, Carlijn A. M.
    Vennalaganti, Sreekar
    Vennalaganti, Prashanth
    Bansal, Ajay
    Falk, Gary
    Lieberman, David
    Sampliner, Richard
    Thota, Prashanthi
    Vargo, John
    Gupta, Neil
    Moawad, Fouad
    Bruno, Marco
    Kennedy, Kevin F.
    Gaddam, Srinivas
    Young, Patrick
    Mathur, Sharad
    Cash, Brooks
    Spaander, Manon
    Sharma, Prateek
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (04) : 321 - 326